Cost-utility analysis of vortioxetine versus agomelatine, bupropion SR, sertraline and venlafaxine XR after treatment switch in major depressive disorder in Finland

Soini, Erkki; Hallinen, Taru; Brignone, M.; Campbell, Rosanne; Diamand, F.; Cure, S.; Aalto-Setälä, Maria; Danchenko, Natalya; Koponen, Hannu; Kolasa, Katarzyna

doi:10.1080/14737167.2017.1240617

Cited by 20 publications

(39 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Three studies analysed data from Sweden [ 55 , 56 , 59 ] and another two from India [ 58 , 77 ]. The remaining six studies used data from Japan [ 65 ], Greece [ 53 ], Canada [ 74 ], Belgium [ 26 ], Korea [ 34 ] and Finland [ 70 ].…”

Section: Resultsmentioning

confidence: 99%

“…Concerning the perspective, 22 of the studies (42%) applied the societal perspective [ 30 , 38 , 40 – 43 , 45 , 48 , 49 , 53 – 57 , 59 , 63 , 66 , 67 , 69 , 71 – 73 , 76 ]. Eighteen studies conducted an evaluation considering both positions [ 26 – 29 , 31 , 32 , 34 , 37 , 39 , 50 , 51 , 58 , 62 , 64 , 65 , 74 , 75 , 77 ] and 12 focused on the healthcare perspective and calculated societal costs separately [ 33 , 35 , 36 , 44 , 46 , 47 , 52 , 60 , 61 , 65 , 70 , 78 ]. One study did not explain which perspective was used [ 68 ].…”

Section: Resultsmentioning

confidence: 99%

“…Considering the intervention type, 26% of the studies compared two or more different pharmaceuticals [ 26 , 28 , 34 , 36 , 38 , 53 , 55 – 57 , 59 , 62 , 66 , 69 , 70 ], whereby the main part of the articles evaluated non-pharmaceutical interventions such as cognitive behavioural therapy or other psycho-educational therapies. Collaborative care interventions were evaluated in eight studies [ 27 , 40 , 42 – 44 , 49 , 60 , 72 ] and seven articles focused on a combination of pharmaceutical and psychological interventions [ 46 , 50 , 54 , 58 , 65 , 67 , 75 ].…”

Section: Resultsmentioning

confidence: 99%

“…The majority (70%) of the 53 economic evaluation studies included CEA as well as CUA. Regarding the study design, most of the publications reported data from randomized controlled trials (RCT) [ 27 – 33 , 35 , 38 – 44 , 46 , 47 , 49 – 52 , 54 , 58 , 60 – 64 , 66 , 67 , 69 , 71 – 73 , 76 – 78 ] and 16 studies used a modelling approach for the calculations [ 26 , 34 , 36 , 37 , 45 , 48 , 53 , 55 – 57 , 59 , 65 , 68 , 70 , 74 , 75 ].…”

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Considering the societal perspective in economic evaluations: a systematic review in the case of depression

et al. 2020

View full text Add to dashboard Cite

Background Depressive disorders are associated with a high burden of disease. However, due to the burden posed by the disease on not only the sufferers, but also on their relatives, there is an ongoing debate about which costs to include and, hence, which perspective should be applied. Therefore, the aim of this paper was to examine whether the change between healthcare payer and societal perspective leads to different conclusions of cost-utility analyses in the case of depression. Methods A systematic literature search was conducted to identify economic evaluations of interventions in depression, launched on Medline and the Cost-Effectiveness Registry of the Tufts University using a ten-year time horizon (2008–2018). In a two-stepped screening process, cost-utility studies were selected by means of specified inclusion and exclusion criteria. Subsequently, relevant findings was extracted and, if not fully stated, calculated by the authors of this work. Results Overall, 53 articles with 92 complete economic evaluations, reporting costs from healthcare payer/provider and societal perspective, were identified. More precisely, 22 estimations (24%) changed their results regarding the cost-effectiveness quadrant when the societal perspective was included. Furthermore, 5% of the ICURs resulted in cost-effectiveness regarding the chosen threshold (2% of them became dominant) when societal costs were included. However, another four estimations (4%) showed the opposite result: these interventions were no longer cost-effective after the inclusion of societal costs. Conclusions Summarising the disparities in results and applied methods, the results show that societal costs might alter the conclusions in cost-utility analyses. Hence, the relevance of the perspectives chosen should be taken into account when carrying out an economic evaluation. This systematic review demonstrates that the results of economic evaluations can be affected by different methods available for estimating non-healthcare costs.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Considering the societal perspective in economic evaluations: a systematic review in the case of depression

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Although vortioxetine did not dominate in the base case of this study versus venlafaxine XR (which has been on the Chinese market since 2000), vortioxetine consistently dominated versus branded venlafaxine XR across region sensitivity analyses. In previous economic evaluations, vortioxetine has shown dominance versus venlafaxine XR in South Korea 42 , versus duloxetine in Norway 43 , and as a second-line therapy (versus agomelatine, bupropion, venlafaxine and sertraline) in Finland 44 . It should be noted that the cost-effectiveness model applied in this study was based on units of STPs rather than health-economic standard effect measures such as quality-adjusted life years (QALYs) or disability-adjusted life years (DALYs) 45 .…”

Section: Discussionmentioning

confidence: 99%

Successfully treated patients with vortioxetine versus venlafaxine: a simplified cost-effectiveness analysis based on a head-to-head study in Asian patients with major depressive disorder

Wang

Zhao

Reynaud-Mougin

et al. 2020

Current Medical Research and Opinion

View full text Add to dashboard Cite

show abstract

A Promising Approach to Optimizing Sequential Treatment Decisions for Depression: Markov Decision Process

Jörg

et al. 2022

PharmacoEconomics

View full text Add to dashboard Cite

The most appropriate next step in depression treatment after the initial treatment fails is unclear. This study explores the suitability of the Markov decision process for optimizing sequential treatment decisions for depression. We conducted a formal comparison of a Markov decision process approach and mainstream state-transition models as used in health economic decision analysis to clarify differences in the model structure. We performed two reviews: the first to identify existing applications of the Markov decision process in the field of healthcare and the second to identify existing health economic models for depression. We then illustrated the application of a Markov decision process by reformulating an existing health economic model. This provided input for discussing the suitability of a Markov decision process for solving sequential treatment decisions in depression. The Markov decision process and state-transition models differed in terms of flexibility in modeling actions and rewards. In all, 23 applications of a Markov decision process within the context of somatic disease were included, 16 of which concerned sequential treatment decisions. Most existing health economic models relating to depression have a state-transition structure. The example application replicated the health economic model and enabled additional capacity to make dynamic comparisons of more interventions over time than was possible with traditional state-transition models. Markov decision processes have been successfully applied to address sequential treatment-decision problems, although the results have been published mostly in economics journals that are not related to healthcare. One advantage of a Markov decision process compared with state-transition models is that it allows extended action space: the possibility of making dynamic comparisons of different treatments over time. Within the context of depression, although existing state-transition models are too basic to evaluate sequential treatment decisions, the assumptions of a Markov decision process could be satisfied. The Markov decision process could therefore serve as a powerful model for optimizing sequential treatment in depression. This would require a sufficiently elaborate state-transition model at the cohort or patient level.

show abstract

Cost-utility analysis of vortioxetine versus agomelatine, bupropion SR, sertraline and venlafaxine XR after treatment switch in major depressive disorder in Finland

Abstract: This cost-utility analysis showed vortioxetine to be a good alternative for MDD patients switching therapy in Finland.

Cited by 20 publications

References 30 publications

Considering the societal perspective in economic evaluations: a systematic review in the case of depression

Considering the societal perspective in economic evaluations: a systematic review in the case of depression

Successfully treated patients with vortioxetine versus venlafaxine: a simplified cost-effectiveness analysis based on a head-to-head study in Asian patients with major depressive disorder

A Promising Approach to Optimizing Sequential Treatment Decisions for Depression: Markov Decision Process

Contact Info

Product

Resources

About